Helix BioPharma Financials
| HBP Stock | CAD 0.77 0.07 10.00% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.88 | 0.9221 |
|
|
Helix | Select Account or Indicator |
Understanding current and past Helix BioPharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Helix BioPharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Helix BioPharma's assets may result in an increase in income on the income statement.
Helix BioPharma Stock Summary
Helix BioPharma competes with Microbix Biosystems, Oncolytics Biotech, Spectral Med, and Theratechnologies. Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. Helix BioPharma Corp. is headquartered in Richmond Hill, Canada. HELIX BIOPHARM operates under Biotechnology classification in Canada and is traded on Toronto Stock Exchange. It employs 22 people.| Foreign Associates | |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | Canada Stock View All |
| Exchange | Toronto Exchange |
| ISIN | CA4229101098 |
| Business Address | 1055 West Georgia |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.helixbiopharma.com |
| Phone | 905 841 2300 |
| Currency | CAD - Canadian Dollar |
You should never invest in Helix BioPharma without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Helix Stock, because this is throwing your money away. Analyzing the key information contained in Helix BioPharma's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Helix BioPharma Key Financial Ratios
Helix BioPharma's financial ratios allow both analysts and investors to convert raw data from Helix BioPharma's financial statements into concise, actionable information that can be used to evaluate the performance of Helix BioPharma over time and compare it to other companies across industries.| Return On Equity | -22.21 | ||||
| EBITDA | (9.22 M) | ||||
| Net Income | (9.26 M) | ||||
| Cash Per Share | 0.01 X | ||||
| Current Ratio | 0.37 X |
Helix BioPharma Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 4.9M | 4.1M | 3.7M | 1.0M | 1.5M | 1.4M | |
| Other Current Liab | 49K | 380K | (1K) | 1.4M | 1.2M | 1.3M | |
| Net Debt | (4.1M) | 47K | (784K) | (808K) | (929.2K) | (975.7K) | |
| Retained Earnings | (180.5M) | (188.6M) | (195.1M) | (201.4M) | (210.7M) | (221.2M) | |
| Accounts Payable | 1.4M | 1.5M | 599K | 493K | 855K | 1.1M | |
| Cash | 4.2M | 3.6M | 3.3M | 808K | 1.1M | 1.0M | |
| Net Receivables | 180K | 353K | 280K | 62K | 55.8K | 53.0K | |
| Other Current Assets | 245K | 100K | (1K) | 126K | 113.4K | 179.3K | |
| Total Liab | 1.9M | 5.5M | 3.4M | 1.9M | 1.6M | 2.4M | |
| Total Current Assets | 4.7M | 4.0M | 3.7M | 996K | 1.5M | 1.4M | |
| Net Tangible Assets | (3.3M) | 2.4M | (1.4M) | 319K | 287.1K | 272.7K | |
| Common Stock | 137.3M | 139.7M | 147.5M | 152.1M | 174.9M | 127.4M | |
| Capital Surpluse | 25.5M | 27.9M | 37.6M | 44.1M | 50.8M | 29.9M | |
| Net Invested Capital | 2.4M | 2.2M | 2.8M | (844K) | (90K) | (85.5K) | |
| Net Working Capital | 2.7M | 144K | 284K | (878K) | (123K) | (129.2K) | |
| Capital Stock | 137.3M | 139.7M | 147.5M | 152.1M | 158.6M | 155.6M |
Helix Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Helix BioPharma's current stock value. Our valuation model uses many indicators to compare Helix BioPharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Helix BioPharma competition to find correlations between indicators driving Helix BioPharma's intrinsic value. More Info.Helix BioPharma Corp is rated # 5 in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Helix BioPharma's Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Helix BioPharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Helix BioPharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Helix BioPharma Corp Systematic Risk
Helix BioPharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Helix BioPharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Helix BioPharma Corp correlated with the market. If Beta is less than 0 Helix BioPharma generally moves in the opposite direction as compared to the market. If Helix BioPharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Helix BioPharma Corp is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Helix BioPharma is generally in the same direction as the market. If Beta > 1 Helix BioPharma moves generally in the same direction as, but more than the movement of the benchmark.
Helix BioPharma Corp Total Assets Over Time
Today, most investors in Helix BioPharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Helix BioPharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Helix BioPharma growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Helix BioPharma November 23, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Helix BioPharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Helix BioPharma Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of Helix BioPharma Corp based on widely used predictive technical indicators. In general, we focus on analyzing Helix Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Helix BioPharma's daily price indicators and compare them against related drivers.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 46.6 | |||
| Value At Risk | (10.62) | |||
| Potential Upside | 9.35 |
Other Information on Investing in Helix Stock
Helix BioPharma financial ratios help investors to determine whether Helix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioPharma security.